<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACETAMINOPHEN AND CODEINE PHOSPHATE- acetaminophen and codeine phosphate tablet </strong><br>McKesson Contract Packaging<br></p></div>
<h1>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP CIII<br>0050<br>0150<br>0350<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bd782ef5-d305-41a6-bfe3-67fbcbc2c463"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acetaminophen and codeine is supplied in tablet form for oral administration.</p>
<p>Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:</p>
<div class="Figure">
<img alt="Structural Formula for Acetaminophin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61f11bc0-02e7-47ea-a05b-39c590844bf9&amp;name=79fb3828-3b00-4b01-a135-b3ca456168ed-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2 </span> M.W. 151.16</p>
<p>Codeine phosphate, 7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate, a white crystalline powder, is a narcotic analgesic and antitussive. It has the following structural formula:</p>
<p><img alt="Structural formula for codeine phosphate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61f11bc0-02e7-47ea-a05b-39c590844bf9&amp;name=79fb3828-3b00-4b01-a135-b3ca456168ed-02.jpg"></p>
<p>C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">3</span>•H<span class="Sub">3</span>PO<span class="Sub">4</span>•1/2H<span class="Sub">2</span>O M.W. 406.37</p>
<p>Each tablet contains:</p>
<p>acetaminophen...........................300 mg</p>
<p>codeine phosphate.......................15 mg</p>
<p>(Warning: May be habit forming)</p>
<p>OR</p>
<p>acetaminophen...........................300 mg</p>
<p>codeine phosphate....................... 30 mg</p>
<p>(Warning: May be habit forming)</p>
<p>OR</p>
<p>acetaminophen...........................300 mg</p>
<p>codeine phosphate....................... 60 mg</p>
<p>(Warning: May be habit forming)</p>
<p>In addition, each tablet contains the following inactive ingredients: corn starch, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The 300 mg/60 mg strength tablets also contain crospovidone, povidone, pregelatinized starch, and stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c891b6c3-331f-4926-8fe6-3de29438e373"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">This product combines the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_81710940-4be5-4471-a1ee-85a4ad70f7fa"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The behavior of the individual components is described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ae2cbdf-72b4-4800-99ab-b5d91906919e"></a><a name="section-2.1.1"></a><p></p>
<h3>Codeine</h3>
<p class="First">Codeine is readily absorbed from the gastrointestinal tract. It is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen and kidney. Codeine crosses the blood-brain barrier, and is found in fetal tissue and breast milk. The plasma concentration does not correlate with brain concentration or relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; however, codeine is not bound to plasma proteins and does not accumulate in body tissues.</p>
<p>The plasma half-life is about 2.9 hours. The elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. The urinary secretion products consist of free and glucuronide conjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (4%), and hydrocodone (1%). The remainder of the dose is excreted in the feces.</p>
<p>At therapeutic doses, the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> reaches a peak within 2 hours and persists between 4 and 6 hours.</p>
<p>See <span class="Bold">OVERDOSAGE </span>for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_903e8556-2cd9-45c5-a5f6-efdc88bdc893"></a><a name="section-2.1.2"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.</p>
<p>See <span class="Bold">OVERDOSAGE </span>for toxicity information.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_71396107-56f2-4076-8e4e-416978e647a0"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2d656bb5-6924-41d1-ad2e-9a39400be395"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product should not be administered to patients who have previously exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to codeine or acetaminophen.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1f33c4e4-5cca-4a93-999b-847bb3e8e961"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or other intracranial lesions, the respiratory depressant effects of codeine and other narcotics may be markedly enhanced, as well as their capacity for elevating cerebrospinal fluid pressure. Narcotics also produce other CNS depressant effects, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, that may further obscure the clinical course of the patients with head injuries.</p>
<p>Codeine or other narcotics may obscure signs on which to judge the diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p>Codeine is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfd78867-9e40-4608-a724-7594c8869579"></a><a name="section-5.1"></a><p></p>
<h2>Alcohol Information</h2>
<p class="First">Chronic heavy alcohol abusers may be at increased risk of liver toxicity from excessive acetaminophen use, although reports of this event are rare. Reports almost invariably involve cases of severe chronic alcoholics and the dosages of acetaminophen most often exceed recommended doses and often involve substantial <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Professionals should alert their patients who regularly consume large amounts of alcohol not to exceed recommended doses of acetaminophen.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_05428e8c-641a-4ca1-9fee-ecb17745f164"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_cd8d6043-97e3-4e71-b0e1-8fc8906034d9"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Acetaminophen and codeine phosphate tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, head injuries, elevated intracranial pressure, acute abdominal conditions, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, Addison's disease, or <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5bef21a6-36e2-4763-8210-4be395692ba7"></a><a name="section-6.1.1"></a><p></p>
<h3>Ultra-Rapid Metabolizers of Codeine</h3>
<p class="First">Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6<span class="Sup">*</span>2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regiments, individuals who are ultra-rapid metabolizers may experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">Nursing Mothers</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7e2c0e42-2768-4d74-8aef-103ccfe40682"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Caution patients that some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.</p>
<p>Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).</p>
<p>Codeine may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.</p>
<p>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, when taken with this combination product, and should be avoided.</p>
<p>Codeine may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_2028ba19-86a5-4ce8-8f81-32dbfe86bcc1"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_816350ac-905d-4d95-9c4f-c648b5d10118"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">This drug may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_32f4d542-85e4-4801-9ce0-445a313b0b61"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Codeine may increase serum amylase levels.</p>
<p>Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_62e98240-feaa-44a5-8684-241944ff336b"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen and codeine have a potential for carcinogenesis or mutagenesis. No adequate studies have been conducted in animals to determine whether acetaminophen has a potential for impairment of fertility.</p>
<p>Acetaminophen and codeine have been found to have no mutagenic potential using the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_7b1c1251-cf74-43f3-92be-849cd640c27c"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_b4157dd6-669d-4083-a264-344dfef41a2a"></a><a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2bdfb933-9a7d-4901-baa5-f35c00c37c89"></a><a name="section-6.7.1.1"></a><p></p>
<h4>Pregnancy category C</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3b4cfd9-3da7-4f52-b44a-a7e4b9728336"></a><a name="section-6.7.1.1.1"></a><p></p>
<h5>Codeine</h5>
<p class="First">A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100 mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Acetaminophen and codeine phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_958f8239-9c0a-4d5d-93c1-f03ed43a189b"></a><a name="section-6.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> has been reported in newborns whose mothers took opiates regularly during pregnancy. Withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. These signs usually appear during the first few days of life.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_e80a6fcd-6cef-4f26-ac00-e33df1c9e5eb"></a><a name="section-6.8"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Resuscitation may be required (see <span class="Bold">OVERDOSAGE</span>). The effect of codeine, if any, on the later growth, development, and functional maturation of the child is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_017d7b6e-58a6-4c73-922d-2b01bf257ad1"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. Because of the potential for serious adverse reactions in nursing infants from acetaminophen, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in nursing infants.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.</p>
<p>The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">General</span>, <span class="Bold"><span class="Italics">Ultra-Rapid Metabolizers of Codeine</span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e93e6339-b712-4d55-82fe-b2a654c18cc9"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects seem to be more prominent in ambulatory than in non-ambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down.</p>
<p>Other adverse reactions include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>At higher doses codeine has most of the disadvantages of morphine including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_f2e6534f-1027-48c4-b230-369da829d91e"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_210f1e61-d0fd-40e8-84ac-06f839013d24"></a><a name="section-8.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">Acetaminophen and codeine phosphate tablets are classified as a Schedule III controlled substance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41d5f44c-fadc-451e-9452-4971cdd44fc6"></a><a name="section-8.2"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Codeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and, therefore, has the potential for being abused. Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5c39e87d-ae72-4389-88f1-a19280227d35"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage, toxicity may result from codeine or acetaminophen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89919996-bfbf-4241-b195-c0602839b647"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Bold"><span class="Italics">codeine</span></span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes the opioid triad of: pinpoint pupils, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may occur.</p>
<p>In <span class="Italics"><span class="Bold">acetaminophen</span></span> overdosage: dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
<p>In adults, hepatic toxicity has rarely been reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> of less than 10 grams, or fatalities with less than 15 grams.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb0f09b9-a308-4d5e-b68b-5bbba76c1b02"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with acetaminophen and codeine is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. </p>
<p>Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should respond to fluids. Vasopressors and other supportive measures should be employed as indicated. A cuffed endo-tracheal tube should be inserted before gastric lavage of the <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patient and, when necessary, to provide assisted respiration.</p>
<p>Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, peritoneal dialysis, or preferably hemodialysis may be considered. If <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> occurs due to acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, vitamin K should be administered intravenously.</p>
<p>Naloxone, a narcotic antagonist, can reverse <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> associated with opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Naloxone hydrochloride 0.4 mg to 2 mg is given parenterally. Since the duration of action of codeine may exceed that of the naloxone., the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen levels should be obtained since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not  await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24 hour intervals.</p>
<p><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> over 30% should be treated with methylene blue by slow intravenous administration.</p>
<p><span class="Bold">Toxic Doses (For Adults)</span></p>
<p>Acetaminophen: toxic dose 10 g</p>
<p>Codeine: toxic dose 240 mg</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_0a672841-57e2-4c73-b502-f49c5f34ac51"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be adjusted according to severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and response of the patient.</p>
<p>The usual <span class="Bold">adult </span>dosage is:</p>
<a name="id_2ab68100-b8ec-4fc0-9250-00096ce8a7eb"></a><table border="1" width="325.000">
<col width="28.9%">
<col width="31.7%">
<col width="39.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle">Single Doses (range)</td>
<td class="Botrule Rrule" align="left" valign="middle">Maximum 24 Hour Dose</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Codeine Phosphate</td>
<td class="Botrule Rrule" align="left" valign="middle">15 mg to 60 mg</td>
<td class="Botrule Rrule" align="left" valign="middle">360 mg</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Acetaminophen</td>
<td class="Rrule" align="left" valign="middle">300 mg to 1000 mg</td>
<td class="Botrule Rrule" align="left" valign="middle">4000 mg</td>
</tr>
</tbody>
</table>
<p>The usual dose of codeine phosphate in <span class="Bold">children </span>is 0.5 mg/kg.</p>
<p>Doses may be repeated up to every 4 hours.</p>
<p>The prescriber must determine the number of tablets per dose, and the maximum number of tablets per 24 hours based upon the above dosage guidance. This information should be conveyed in the prescription.</p>
<p>It should be kept in mind, however, that tolerance to codeine can develop with continued use and that the incidence of untoward effects is dose related. Adult doses of codeine higher than 60 mg fail to give commensurate relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> but merely prolong <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and are associated with an appreciably increased incidence of undesirable side effects. Equivalently high doses in children would have similar effects.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_657cd0f7-bd3c-4bef-9fa6-a6dd7d2993dd"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Acetaminophen and codeine phosphate tablets USP (white, round, unscored):</p>
<p>List No. 0050, acetaminophen 300 mg and codeine phosphate 15 mg, debossed "2" on one side and "TV"-"50" on the other side of tablet is available in bottles of 100 tablets.</p>
<p>List No. 0150, acetaminophen 300 mg and codeine phosphate 30 mg, debossed "3" on one side and "TV"- "150" on the other side of tablet is available in bottles of 100 and 1000 tablets, and in unit-dose boxes of 100 (10 x 10) tablets.</p>
<p>List No. 0350, acetaminophen 300 mg and codeine phosphate 60 mg, debossed "4" on one side and "93"- "350" on the other side of tablet is available in bottles of 100, 500, and 1000 tablets.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from moisture.</p>
<p>PROTECT FROM LIGHT</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p><span class="Bold">TEVA PHARMACEUTICALS </span><span class="Bold">USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. AB 9/2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_994b9d03-cc35-46fe-a437-88a081fe7da2"></a><a name="section-12"></a><p></p>
<h1>Package Display Panel</h1>
<p class="First"><img alt="Bingo card image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61f11bc0-02e7-47ea-a05b-39c590844bf9&amp;name=79fb3828-3b00-4b01-a135-b3ca456168ed-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETAMINOPHEN AND CODEINE PHOSPHATE 		
					</strong><br><span class="contentTableReg">acetaminophen and codeine phosphate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76237-103(NDC:0093-0150)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">300 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CODEINE PHOSPHATE</strong> (CODEINE ANHYDROUS) </td>
<td class="formItem">CODEINE PHOSPHATE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3;TV;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76237-103-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088628</td>
<td class="formItem">10/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>McKesson Contract Packaging
							(968953377)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>McKesson Packaging Services a business unit of McKesson Corporation (140529962)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">McKesson Packaging Services a business unit of McKesson Corporation</td>
<td class="formItem"></td>
<td class="formItem">140529962</td>
<td class="formItem">REPACK(76237-103)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>79fb3828-3b00-4b01-a135-b3ca456168ed</div>
<div>Set id: 61f11bc0-02e7-47ea-a05b-39c590844bf9</div>
<div>Version: 2</div>
<div>Effective Time: 20111021</div>
</div>
</div> <div class="DistributorName">McKesson Contract Packaging</div></p>
</body></html>
